POS0740 EPIDEMIOLOGY AND CLINICAL FEATURES OF OCULAR SARCOIDOSIS. STUDY OF 65 PATIENTS OF A SERIES OF 384 PATIENTS FROM A SINGLE UNIVERSITY HOSPITAL
Authors: C. Álvarez-Reguera, J. J. Gaitán-Valdizán, R. Fernández-Ramón, R. Demetrio-Pablo, J. L. Martín-Varillas, L. Sanchez-Bilbao, D. Martínez-López, I. González-Mazón, M. Á. González-Gay, R. Blanco
Journal: Annals of the Rheumatic Diseases (2021)

Background: Ocular involvement in sarcoidosis can be present in up to 80% of patients. If not treated, it can lead to significant visually complications (1-5). Objectives: Our aim was to assess the main a ) epidemiology and b ) clinical features of ocular sarcoidosis in a wide and unselected series from a single university hospital. Methods: Study of a large cohort (n=384) of all consecutive patients diagnosed with sarcoidosis from January 1, 1999 to December 31, 2019. Finally, 344 patients were included according to the ATS/ERS/WASOG criteria (Eur Respir J. 1999;14:735-7). Results: 65 (33 men/32 women) of 344 (18.9%) patients had ocular involvement. Mean age at diagnosis was 45.6±15.9 years. The most frequent extraocular clinical clusters were respiratory (80%), osteoarticular (30.8%) and cutaneous (29.2%) (figure 1). Ocular manifestations and complications are shown in table 1. Uveitis (83.1%), orbital lesions (7.7%) and retinal vasculitis (6.2%) were the most common ocular lesions. Median Best Corrected Visual Acuity (BCVA) at diagnosis and after one year of follow-up was 0.6 [0.3-0.8] and 0.9 [0.30-1], respectively. Retinal vasculitis was associated to the worst BCVA outcome, and panuveitis to more frequent and severe complications. Conclusion: Ocular manifestations, especially uveitis, are frequent in sarcoidosis. A more aggressive and early treatment may be indicated in panuveitis and retinal vasculitis. References: [1]Riancho-Zarrabeitia L, et al. Semin Arthritis Rheum 2015;45:361-8. [2]Riancho-Zarrabeitia L et al. Clin Exp Rheumatol 2014; 32:275-84. [3]Vegas-Revenga N, et al. Am J Ophthalmol 2019; 200:85-94. [4]Calvo-Río V, et al. Clin Exp Rheumatol 2014; 32 (4 Suppl 84): S54-7. Epub 2014 Jul 8. [5]Cordero-Coma et al. Mediators Inflamm. 2014; 2014:717598. Figure 1. Clinical clusters of associations in ocular sarcoidosis. Table 1. Ocular manifestations and associated complications after 1 year of follow-up of 65 patients with ocular sarcoidosis. Type of ocular affectation N (% ) Median BCVA at onset [IQR] Median BCVA after 1 year of follow-up [IQR] Cataract N (% ) OP N (% ) OHT N (% ) CME N (% ) ERM N (% ) Uveitis, pattern 54 (83.1) 0.6 [0.3-0.8] 0.9 [0.6-1] 18 (27.7) 11 (16.9) 7 (10.8) 7 (10.8) 8 (12.3) Anterior 31 (47.7) 0.7 [0.3-0.8] 0.8 [0.5-1] 13 (41.9) 2 (6.5) 2 (6.5) 2 (6.5) 2 (6.5) Panuveitis 16 (24.6) 0.4 [0.2-0.7] 0.9 [0.5-1] 5 (31.3) 7 (43.8) 4 (25) 5 (31.3) 5 (31.3) Posterior 5 (5.2) 0.5 [0.1-0.9] 0.9 [0.9-1] 0 2 (40) 1 (20) 0 0 Intermediate 2 (3.1) 0.5 0.7 0 0 0 0 1 Orbitary lesions 5 (7.7) 0.5 [0.1-0.6] 1 [0.1-1] 1 (20) 0 1 (20) 0 0 Retinal vasculitis 4 (6.2) 0.6 [0.5-0.8] 1 [0.6-1] 0 0 0 0 1 (25) Dry eye 4 (6.2) 1 0.9 0 0 0 0 0 Scleritis 1 0.6 1.0 0 0 0 0 0 Abbreviations : BCVA: Best corrected visual acuity; CME: Cystoid macular edema ERM: Epiretinal membrane; OP: Optic Papillitis; OHT: Ocular hypertension. Disclosure of Interests: Carmen Álvarez-Reguera: None declared, Jorge Javier Gaitán-Valdizán: None declared, Raúl Fernández-Ramón: None declared, Rosalía Demetrio-Pablo: None declared, José Luis Martín-Varillas: None declared, Lara Sanchez-Bilbao: None declared, David Martínez-López: None declared, Iñigo González-Mazón: None declared, Miguel Á. González-Gay Speakers bureau: Abbvie, Pfizer, Roche, Sanofi and MSD., Grant/research support from: Abbvie, MSD, Janssen and Roche., Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myer, Janssen, Lilly and MSD., Grant/research support from: Abbvie, MSD and Roche.